Type 2 diabetes mellitus and cancer

Diabetologia Doswiadczalna i Kliniczna

Volumn 7, Issue 6, 2007, Pages 268-275

  Sliwinska, Agnieszka ^a   Drzewoski, Jozef ^a,b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b Klinika Chorob Wewnetrznych Z Oddzialem Diabetologii I Farmakologii Klinicznej UM W Lodzi   (Poland)

Author keywords

Cancer; Insulin; Oral hypoglycaemic drugs; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLIBENCLAMIDE; GLICLAZIDE; GLITAZONE DERIVATIVE; INSULIN; METFORMIN; SULFONYLUREA;

CANCER RISK; CELL DEATH; CELL PROLIFERATION; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG MECHANISM; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN RESISTANCE; LUNG CANCER; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSTATE CANCER; REVIEW; RISK FACTOR;

EID: 39449128952     PISSN: 16433165     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Coughlin SS, Calle EE, Teras LR. et al. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 2004; 159: 1160-1167.
2. Ko C, Chaudhry S. The need for a multidisciplinary approach to cancer care. J Surg Res 2002; 105: 53-57.
3. Psarakis HM. APRN. Clinical challenges in caring for patients with diabetes and cancer. Diabetes Spectrum 2006; 19: 157-162.
4. Freund E. Zur diagnose des carcinoms. Wiener Medizinische BI 1985; 8: 268-269.
5. Shaw JE, Hodge AM, de Courten M. et al. Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality. Diabetologia 1999; 42: 1050-1054.
6. Saydah SH, Loria CM, Eberhardt MS, Brancati FL. Abnormal glucose tolerance and the risk of cancer death in the United States. Am J Epidemiol 2003; 157: 1092-1100.
7. Stattin P, Bjor O, Ferrari P. et al. Prospective study of hyperglyceamia and cancer risk. Diabetes Care 2007; 30: 561-567.
8. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004; 4: 579-591.
9. Lorenzi M, Montisano DF, Toledo S, Barrieux A. High glucose induces DNA damage in cultured human endothelial cells. J Clin Invest 1986; 77: 322-325.
10. Dandona P, Thusu K, Cook S. et al. Oxidative damage to DNA in diabetes mellitus. Lancet 1996; 347: 444-445.
11. Caimi G, Carollo C, Lo Presti R. Diabetes mellitus: oxidative stress and wine. Curr Med Res Opin 2003; 19: 581-586.
12. Yakes FM, Van Houten B. Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress. Proc Natl Acad Sci USA 1997; 94: 514-519.
13. Bandy D, Davison AJ. Mitochondrial mutations may increase oxidative stress: implications for carcinogenesis and aging? Free Radic Biol Med 1990; 8: 523-539.
14. Seril DN, Liao J, Yang GY, Yang CS. Oxidative stress and ulcerative colitis: associated carcinogenesis: studies in humans and animal models. Carcinogenesis 2003; 3: 353-362.
15. Blasiak J, Arabski M, Krupa R. et al. DNA damage and repair in type 2 diabetes mellitus. Mutat Res 2004; 554: 297-304.
16. Merkel P, Khoury N, Bertolotto C, Perfetti R. Insulin and glucose regulate the expression of the DNA repair enzyme XPD. Mol Cell Endocrinol 2003; 201: 75-85.
17. Dincer Y, Akcay T, Alademir Z, Ilkova H. Assessment of DNA base oxidation and glutathione level in patients with type 2 diabetes. Mut Res 2002; 505: 75-81.
18. Song F, Jia W, Yao Y. et al. Oxidative stress, antioxidant status and DNA damage in patients with impaired glucose regulation and newly diagnosed type 2 diabetes. Clin Sci Lond 2007; 112: 599-606.
19. Giovannucci E, Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 2007; 132: 2208-2225.
20. Schiel R, Beltschikow W, Steiner T, Stein G. Diabetes, insulin, and risk of cancer. Methods Find Exp Clin Pharmacol 2006; 28: 169-175.
21. Yamagata H, Kiyohara Y, Nakamura S. et al. Impact of fasting plasma glucose levels on gastric cancer incidence in a general Japanese population: the Hisayama study. Diabetes Care 2005; 28: 789-794.
22. Jee SH, Ohrr H, Sull JW. et al. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005; 293: 194-202.
23. Rapp K, Schroeder J, Klenk J. et al. Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. Diabetologia 2006; 49: 945-952.
24. Michaud DS, Liu S, Giovannucci E. et al. Dietary sugar, glycemic load, and pancreatic cancer risk in a prospective study. J Natl Cancer Inst 2002; 94: 1293-1300.
25. Higginbotham S, Zhang ZF, Lee IM. et al. Women's Health Study. Dietary glycemic load and risk of colorectal cancer in the Women's Health Study. J Natl Cancer Inst 2004; 96: 229-233.
26. Tsuji S, Kawai N, Tsujii M. et al. Review article: inflammation-related promotion of gastrointestinal carcinogenesis - a perigenetic pathway. Aliment Pharmacol Ther 2003 (1 Suppl): 82-89.
27. Holden RJ, Pakula IS, Mooney PA. Tumour necrosis factor-alpha: a continuum of liability between insulin-dependent diabetes mellitus, non-insulin-dependent diabetes mellitus and carcinoma (review). Med Hypotheses 1999; 52: 319-323.
28. Ujpál M, Matos O, Bíbok G. et al. Diabetes and oral tumours in Hungary epidemiological correlations. Diabetes Care 2004; 27: 770-774.
29. Gatti LL, Burbano RR, de Assumpção PP. et al. Interleukin-1beta polymorphisms, Helicobacter pylori infection in individuals from Northern Brazil with gastric adenocarcinoma. Clin Exp Med 2004; 4: 93-98.
30. Stocks T, Lukanova A, Rinaldi S. et al. Insulin resistance is inversely related to prostate cancer: a prospective study in Northern Sweden. Int J Cancer 2007; 120: 2678-2686.
31. van der Burg BB, Rutteman GR, Blankenstein MA. et al. Mitogenic stimulation of human breast cancer cells in a growth-defined medium: synergistic action of insulin and estrogen. J Cell Physiol 1988; 134: 101-108.
32. Barker BE, Fanger H, Farnes P. Human mammary slices in organ culture. I. Methods of culture and preliminary observations on the effects of insulin. Exp Cell Res 1964; 35: 437-448.
33. Kaaks R, Toniolo P, Akhmadkhanov A. Serum C-peptide, insulin-like growth factor (IGF-1), IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 2000; 92: 1592-1600.
34. Rosenfeld RG. Insulin-like growth factors and the basis of growth. N Engl J Med 2003; 349: 2184-2186.
35. Ogihara S, Yamada M, Saito T. et al. Insulin potentiates mitogenic effect of epidermal growth factor on cultured guinea pig gastric mucous cells. Am J Physiol 1996; 271: 104-112.
36. Calle EE, Thun MJ, Petrelli JM. et al. Body-mass index and mortality in a prospective cohort of US adults. N Engl J Med 1999; 341: 1097-1105.
37. Schoen RE, Tangen CM, Kuller LH. Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst 1999; 91: 1147-1154.
38. Bianchini F, Kaaks R, Vainio H, Overweight, obesity, and cancer risk. Lancet Oncol 2002; 3: 565-574.
39. Bray GA. The underlying basis for obesity: relationship to cancer. J Nutr 2002; Suppl 11: 3451-3455.
40. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospective-ly studied cohort of US adults. N Engl J Med 2003; 348: 1625-1638.
41. Guastamacchia E, Resta F, Triggiani V. et al. Evidence for a putative relationship between type 2 diabetes and neoplasia with particular reference to breast cancer: role of hormones, growth factors and specific receptors. Curr Drug Targets Immune Endocr Metabol Disord 2004; 4: 59-66.
42. Nelson R, Persky V, Davis F, Becker E. Excess risk of primary liver cancer in patients with diabetes mellitus [letter]. J Natl Cancer Inst 1997; 89: 327-328.
43. Nelson R, Persky V, Davis F. Diabetes mellitus and risk of large bowel cancer [letter]. J Natl Cancer Inst 1997; 89: 1232.
44. Garmendia ML, Pereira A, Alvarado ME, Atalah E. Relation between insulin resistance and breast cancer among Chilean women. Ann Epidemiol 2007; 17: 403-409.
45. Kaklamani E, Trichpoulos A, Tzonou A. et al. Hapatitis B and C viruses and their interaction in the origin of hepatocellular carcinoma. JAMA 1991; 265: 1974-1976.
46. De Fea K, Roth RA. Modulation of insulin receptor substrate-1 tyrosine phosphorylation and function any mitogen-activated protein kinase. J Biol Chem 1997; 272: 31400-31406.
47. Yang Y, Hennessy S, Lewis JD. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 2004; 127: 1044-1050.
48. Schiel R, Müller UA, Braun A. et al. Risk of malignancies in patients with insulin-treated diabetes mellitus: results of a population-based trial with 10-year follow-up (JEVIN). Eur J Med Res 2005; 10: 339-344.
49. Chuang TY, Lewis DA, Spandau DF. Decreased incidence of nonmelanoma skin cancer in patients with type 2 diabetes mellitus using insulin: a pilot study. Br J Dermatol 2005; 153: 552-557.
50. Tavakkol A, Elder JT, Griffiths CE. et al. Expression of growth hormone receptor, insulin-like growth factor 1 (IGF-1) and IGF-1 receptor mRNA and proteins in human skin. J Invest Dermatol 1992; 99: 343-349.
51. Kath R, Schiel R, Müller UA, Höffken K. Malignancies in patients with insulin-treated diabetes mellitus. J Cancer Res Clin Oncol 2000; 126: 412-417.
52. Kacalska O, Krzyczkowska-Sendrakowska M, Milewicz T. et al. Molekularne podstawy antynowotworowego dzialania uwrazliwiaczy na insuline. Endokrynologia Polska 2005; 56: 309-313.
53. Berstein LM. Clinical usage of hypolipidemic and antidiabetic drugs in the prevention and treatment of cancer. Cancer Letters 2005; 224: 203-212.
54. Hawley SA. et al. Complexes between the LKB1 tumour suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2003; 2: 28.
55. Lizcano JM, Göransson O, Toth R. et al. LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J 2004; 23: 833-843.
56. Bauman AE. Updating the evidence that physical activity is good for health: an epidemiological review 2000-2003. J Sci Med Sport 2004; Suppl 1: 6-19.
57. Evans JM, Donnelly LA, Emslie-Smith AM. et al. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330: 1304-1305.
58. Yki-Jarvinen H. Grud therapy. Thiazolodinediones. NEJM 2004; 351: 1106-1118.
59. Miyazaki Y, Mahankali A, Matsuda M. et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87: 2784-2791.
60. Elstner E, Müller C, Koshizuka K. et al. Ligands for peroxisome proliferators-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 1998; 95: 8806-8811.
61. Kubota T, Koshizuka K, Williamson EA. et al. Ligand for peroxisome proliferators-activated receptor gamma (troglitazone) has potent antitumour effect against human prostate cancer both in vitro and in vivo. Cancer Res 1998; 58: 3344-3352.
62. Sarraf P, Mueller E, Jones D. et al. Differentiation and reversal of malignant changes in colon cancer through PPAR gamma. Nat Med 1998; 4: 1046-1052.
63. Tsubouchi Y, Sano H, Kawahito Y. et al. Inhibition of human lung cancer cell growth by the peroxisome proliferators-activated receptor-gamma agonists through induction of apoptosis. Biochem Biophys Res Commun 2000; 270: 400-405.
64. Keshamouni VG, Reddy RC, Arenberg DA. et al. Peroxisome proliferators-activated receptor-gamma activation inhibits tumour progression in non-small-cell lung cancer. Oncogene 2004; 23: 100-108.
65. Ohta T, Elnemr A, Yamamoto M. et al. Thiazolidinedione, a peroxisome proliferators-activated receptor-gamma ligand, modulates the E-cadherin/beta-catenin system in a human pancreatic cancer cell line, BxPC-3. Int J Oncol 2002; 21: 37-42.
66. Elnemr A, Ohta T, Iwata K. et al. PPAR gamma ligand (thiazolidinedione) induces growth arrest and differentiation markers of human pancreatic cancer cells. Int J Oncol 2000; 17: 1157-1164.
67. Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferators-activated receptor gamma agonists. Lancet Oncol 2004; 5: 419-429.
68. Polyak K, Lee MH, Erdjument-Bromage H. et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994; 78: 59-66.
69. Yu J, Qiao L, Zimmermann L. et al. Troglitazone inhibits tumour growth in hepatocellular carcinoma in vitro and in vivo. Hepatology 2006; 43: 134-143.
70. Chen GG, Lee JF, Wang SH. et al. Apoptosis induced by activation of peroxisome-proliferator activated receptor-gamma is associated with Bcl-2 and NF-kappaB in human colon cancer. Life Sci 2002; 70: 2631-2646.
71. Chen F, Wang M, O'Connor JP. et al. Phosphorylation of PPAR gamma via active ERK1/2 leads to its physical association with p65 and inhibition of NF-kappa-beta. J Cell Biochem 2003; 90: 732-744.
72. Kim EJ, Park KS, Chung SY. et al. Peroxisome proliferators-activated receptor-gamma activator 15-deoxy-Delta12,14-prostaglandin J2 inhibits neuroblastoma cell growth through induction of apoptosis: association with extracellular signal-regulated kinase signal pathway. J Pharmacol Exp Ther 2003; 307: 505-517.
73. Print CG, Loveland KL, Gibson L. et al. Apoptosis regulator bcl-w is essential for spermatogenesis but appears otherwise redundant. 1998; 95: 12424-12431.
74. Zhang Z, Kumar R, Santen RJ, Song RX. The role of adapter protein Shc in estrogen non-genomic action. Steroids 2004; 69: 523-529.
75. Goetze S, Bungenstock A, Czupalla C. et al. Leptin induces endothelial cell migration through Akt, which is inhibited by PPAR gamma-ligands. Hypertension 2002; 40: 748-754.
76. Liu H, Zang C, Fenner MH. et al. PPAR gamma ligands and ATRA inhibit the invasion of human breast cancer cells in vitro. Breast Cancer Res Treat 2003; 79: 63-74.
77. Govindarajan R, Ratnasinghe L, Simmons DL. et al. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 2007; 12: 1476-1481.
78. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006; 29: 254-258.
79. Monami M, Balzi D, Lamanna C. et al. Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. Diabetes Metab Res Rev 2007; Mar 23: [Epub ahead of print].
80. Sliwinska A, Blasiak J, Drzewoski J. Effect of gliclazide on DNA damage in human peripheral blood lymphocytes and insulinoma mouse cells. Chem Biol Interact 2006; 162: 259-267.